Chris Chun-Yiu Chan

Chris Chun-Yiu Chan

Auto-generated profile, based on publicly available information

Chris Chun-Yiu Chan

State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR 999077, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2022 in Science
Verified
Journal Article
Closed access
Shuofeng YuanShuofeng Yuan
Shuofeng Yuan
ZYZi-Wei Ye
Zi-Wei Ye
RLRonghui Liang
Ronghui Liang
KTKaiming Tang
Kaiming Tang
AZAnna Jinxia Zhang
Anna Jinxia Zhang
Jasper Fuk Woo ChanJasper Fuk Woo Chan
Jasper Fuk Woo Chan
The in vivo pathogenicity, transmissibility, and fitness of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) variant are not well understood. We compared these virological attributes of this new variant of concern (VOC) with those of the Delta (B.1.617.2) variant in a Syrian hamster model of COVID-19. Omicron-infected hamsters lost significantly less body weight and exhibited reduced clinical scores, respiratory tract viral burdens, cytokine and chemokine dysregulation, and lung damage than Delta-infected hamsters. Both variants were highly transmissible through contact transmission. In noncontact transmission studies Omicron demonstrated similar or higher transmissibility than Delta. Delta outcompeted Omicron without selection pressure, but this scenario changed once immune selection pressure with neutralizing antibodies—active against Delta but poorly active against Omicron—was introduced. Next-generation vaccines and antivirals effective against this new VOC are therefore urgently needed.

31 May 2024 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
CCChris Chun-Yiu Chan
Chris Chun-Yiu Chan
QGQian Guo
Qian Guo
JCJasper Fuk-Woo Chan
Jasper Fuk-Woo Chan
KTKaiming Tang
Kaiming Tang
JCJian-Piao Cai
Jian-Piao Cai
Shuofeng YuanShuofeng Yuan
Shuofeng Yuan
There are only eight approved small molecule antiviral drugs for treating COVID-19. Among them, four are nucleotide analogues (remdesivir, JT001, molnupiravir, and azvudine), while the other four are protease inhibitors (nirmatrelvir, ensitrelvir, leritrelvir, and simnotrelvir-ritonavir). Antiviral resistance, unfavourable drug‒drug interaction, and toxicity have been reported in previous studies. Thus there is a dearth of new treatment options for SARS-CoV-2. In this work, a three-tier cell-based screening was employed to identify novel compounds with anti-SARS-CoV-2 activity. One compound, designated 172, demonstrated broad-spectrum antiviral activity against multiple human pathogenic coronaviruses and different SARS-CoV-2 variants of concern. Mechanistic studies validated by reverse genetics showed that compound 172 inhibits the 3-chymotrypsin-like protease (3CLpro) by binding to an allosteric site and reduces 3CLpro dimerization. A drug synergistic checkerboard assay demonstrated that compound 172 can achieve drug synergy with nirmatrelvir in vitro. In vivo studies confirmed the antiviral activity of compound 172 in both Golden Syrian Hamsters and K18 humanized ACE2 mice. Overall, this study identified an alternative druggable site on the SARS-CoV-2 3CLpro, proposed a potential combination therapy with nirmatrelvir to reduce the risk of antiviral resistance and shed light on the development of allosteric protease inhibitors for treating a range of coronavirus diseases.

1 November 2025 in Fundamental Research
Verified
Journal Article
Open access
BWBoqian Wang
Boqian Wang
SYShuofeng Yuan
Shuofeng Yuan
CCChris Chun-Yiu Chan
Chris Chun-Yiu Chan
JTJessica Oi-Ling Tsang
Jessica Oi-Ling Tsang
YHYiwu He
Yiwu He
Jasper Fuk Woo ChanJasper Fuk Woo Chan
Jasper Fuk Woo Chan
Combinatorial drug therapies are generally more effective than monotherapies in treating viral infections. However, it is critical for dose optimization to maximize the efficacy and minimize side effects. Although various strategies have been devised to accelerate the optimization process, their efficiencies were limited by the high noises and suboptimal reproducibility of biological assays. With conventional methods, variances among the replications are used to evaluate the errors of the readouts alone rather than actively participating in the optimization. Herein, we present the Regression Modeling Enabled by Monte Carlo Method (ReMEMC) algorithm for rapid identification of effective combinational therapies. ReMEMC transforms the sample variations into probability distributions of the regression coefficients and predictions. In silico simulations revealed that ReMEMC outperformed conventional regression methods in benchmark problems, and demonstrated its superior robustness against experimental noises. Using COVID-19 as a model disease, ReMEMC successfully identified an optimal 3-drug combination among 10 anti-SARS-CoV-2 drug compounds within two rounds of experiments. The optimal combination showed 2-log and 3-log higher load reduction than non-optimized combinations and monotherapy, respectively. Further workflow refinement allowed identification of personalized drug combinational therapies within 5 days. The strategy may serve as an efficient and universal tool for dose combination optimization.